[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypoxia-brain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypoxia-brain":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,86,114,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100644629","brain-radiotherapy-imaging-for-high-grade-glioma-using-hypoxia-targeting-through-oxygen-enhanced-response-100644629",false,"NCT07670455","Brain Radiotherapy Imaging for High-grade Glioma Using Hypoxia Targeting Through Oxygen-Enhanced Response","BRIGHTER","Inclusion Criteria:\n\n* ≥18yrs.\n* Participants able to communicate with staff and safely comply with the study procedures.\n* Participants to provide informed written consent.\n\nExclusion Criteria:\n\n* Participants with any MRI contraindications including inability to lie flat in MRI scanner, claustrophobia and no foreign bodies, medical devices or other items which are considered an MRI contraindication.\n* Geographically remote patients unable to agree to imaging schedule.\n* Participants with illness or condition which means they cannot understand the requirements of the study.\n* Participants with cardiac or pulmonary disease that are unable to tolerate the flow of oxygen delivered via a mask.\n* Participants who have previously been treated with bleomycin (a chemotherapy used to treat some cancers including Hodgkin lymphoma and germ cell tumours).\n* Participants with contraindications to gadolinium-based contrast agent",true,"ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","High-grade gliomas (HGGs) are the most common type of brain cancer in adults. Life expectancy for patients with HGGs is low. Radiotherapy aims to cure the tumour, but this is hard because HGGs are resistant to treatment. Among the possible causes of resistance may be tumour cells with low-oxygen levels (hypoxia). The investigators know that hypoxia reduces tumour sensitivity to radiotherapy. Using a special imaging technique called oxygen-enhanced MRI (OE-MRI), the investigators can try to identify areas of the tumour with hypoxia. The investigators could then give those areas a higher dose of radiotherapy. This might improve tumour control. This study aims to see if OE-MRI can find low-oxygen areas in HGGs. The study will also assess whether higher radiotherapy doses can be simulated in these regions.\n\nProject summary:\n\n1. Set up the OE-MRI process at Leeds Cancer Centre (LCC). OE-MRI settings will be tested on healthy volunteer participants to ensure the images are as good as possible.\n2. Participant Imaging. Patient participants with HGG will be recruited to take part. OE-MRI will be used to image participants during their treatment and track low-oxygen areas before treatment, halfway through treatment and 3 months after treatment has finished.\n3. Dose Escalation Assessment. Computer programs will be used to design radiotherapy treatments to test if higher radiation doses to the tumour's low-oxygen areas can better control the cancer. This will help understand if this targeted approach has potential benefits. This is modelling and will not alter routine clinical patient participant management.",[27,28,29,30],"High Grade Gliomas","Hypoxia Brain","Glioblastoma (GBM)","Brain Neoplasms, Adult",[32,33,34,35,36,37],"Oxygen-enhanced MRI","OE-MRI","Functional MRI","Hypoxia imaging","Quantitative MRI","Tumour hypoxia","NOT_YET_RECRUITING","2026-06-26",{"date":41,"type":42},"2026-06-30","ACTUAL",{"date":44,"type":21},"2026-09-01",{"date":46,"type":21},"2028-10-31",{"name":48,"class":49},"The Leeds Teaching Hospitals NHS Trust","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":72,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100638153","study-of-the-effects-of-acute-exposure-to-moderate-altitude-hypoxia-on-prospective-memory-100638153","NCT07585227","Study of the Effects of Acute Exposure to Moderate Altitude Hypoxia on Prospective Memory.","Etude Des Effets d'Une Exposition aiguë à l'Hypoxie d'Altitude modérée Sur la mémoire Prospective (HYPRO)","HYPRO","Inclusion Criteria:\n\n* Healthy volunteer\n* Has provided informed consent\n\nExclusion Criteria:\n\n* Individuals who do not understand French\n* Pregnant or breastfeeding women\n* Cardiovascular risk factor\n* Infectious disease within the last 4 weeks\n* Chronic cardiovascular, respiratory, hematological, neurological, psychiatric, or metabolic disease\n* History of epileptic seizures, convulsions, or loss of consciousness\n* Individuals with migraines\n* History of a bleeding disorder\n* History of high blood pressure\n* Current medication use (excluding contraception)\n* History of episodes of altitude intolerance\n* Stay at high altitude (\\> 3,500 m) within the last 3 months\n* Anxiety score on the Hospital Anxiety and Depression (HAD) scale \\> 7\n* Depression score on the HAD scale \\> 7\n* Uncontrollable claustrophobia or a history of panic attacks","45 Years",{"count":60,"type":21},50,[24],"The goal of this study is to investigate whether prospective memory, i.e., memory for delayed intentions, is impaired at moderate altitude (4,000m).\n\nIt will also allow to study the effect of air and oxygen administration during hypoxia exposure.\n\nThe main questions it aims to answer are:\n\n* Does moderate acute hypoxia impair prospective memory ?\n* If so, does air or oxygen adminsitration induce a restoration of prospective memory? Researchers will compare cognitive performance during normobaric hypoxia exposure to cognitive performance during normoxia (control situation).\n\nParticipants will:\n\n* Session S0. Perform a battery of neuropsychological tests and questionnaires). EEG will be recorded during tests. A cheek swab will be performed.\n* Sessions S1 and S2. Perform several cognitive tasks while exposed to hypoxia and to normoxia (2 different sessions, randomized order) in a normobaric chamber. These are standardized cognitive tests administered on a computer and cognitive tests embedded in a flight simulator scenario. Various questionnaires will be performed on a regular basis. Several physiological measurements will be performed continuously: EEG, ECG, SpO2 and breathing rate. Blood pressure will be measured at the beginning and at the end of hypoxia\u002Fnormoxia exposure. A blood sample will also be performed. At last, participants will inhale air or oxygen through a mask while making a cognitive task in the chamber.",[64,28,65,66,67,68,69,70,71],"Hypoxia","Hypoxia Altitude Simulation Test","Hypoxia in Healthy Individuals","Hypoxia, Altitude","Hypoxia, Brain","Altitude","Altitude Hypoxia","Normobaric Hypoxia",[73,74,75],"prospective memory","working memory","flight simulator","2026-05-09",{"date":78,"type":42},"2026-05-13",{"date":80,"type":21},"2026-05-06",{"date":82,"type":21},"2026-12-31",{"name":84,"class":49},"Direction Centrale du Service de Santé des Armées",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100638702","portable-mri-for-pediatric-hypoxic-ischemic-brain-injury-100638702","NCT07577336","Portable MRI for Pediatric Hypoxic Ischemic Brain Injury","Ultralow-Field Portable MRI for Detection of Pediatric Hypoxic Ischemic Brain Injury","pMRI for pHIBI","Inclusion Criteria\n\n* Patients hospitalized in the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit\n* Ages 0-17 years at study enrollment\n* Acute neurologic deficit suspected secondary to Hypoxic Ischemic Brain Injury (HIBI) or patients at high risk for HIBI\n\nExclusion Criteria\n\n* Pregnancy\n* Active implants such as\n\n  * Pacemaker\n  * Implanted defibrillator\n  * Implanted insulin pump\n  * Deep brain stimulator\n  * Vagus nerve stimulator\n  * Cochlear implant\n  * Programmable shunt\n* MRI incompatible surgical hardware (e.g., staples, screws, etc.)\n* Metal-containing tattoos or permanent make-up on head or neck\n* Suspected metal in eye, e.g.,\n* Former or current welders, metal workers, or individuals with a metal injury\n* Metal shrapnel","17 Years",{"count":96,"type":21},200,[24],"This study will evaluate the sensitivity and specificity of low field portable MRI (pMRI) for detection of hypoxic ischemic brain injuries in pediatric patients compared to clinically obtained neuroimaging to define pediatric diagnostic limitations and to determine the diagnostic capabilities of this neuroimaging modality following optimization of image acquisition. The results of this study will help determine optimal clinical implementation opportunities in pediatric patients.",[100,68,101,102,103,104],"Acute Brain Injury","Ischemia, Brain","Brain Injuries","Trauma, Brain","Stroke","2026-05-03",{"date":107,"type":42},"2026-05-11",{"date":109,"type":21},"2026-06",{"date":111,"type":21},"2027-12",{"name":113,"class":49},"Children's Mercy Hospital Kansas City",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":85},"100305377","phase-1-cerebral-blood-flow-and-ventilatory-responses-during-sleep-in-normoxia-and-intermittent-hypoxia-100305377","NCT03255408","Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia","Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia","Inclusion Criteria:\n\n* Healthy adults\n* 18 - 45 years of age\n* Living in Calgary for the past one year\n* Have no medical condition or should not be taking any blood pressure medications.\n* The participant should not be lactose intolerant\n\nExclusion Criteria:\n\n* Cerebrovascular, cardio-respiratory, renal and metabolic diseases\n* Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease\n* Pregnancy, obese and sleep-disordered breathing\n* Drug allergies to non-steroidal anti-inflammatories\n* Currently smoking",{"count":122,"type":21},12,[124,125],"PHASE1","PHASE2","A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).",[128,68,129,130,104,131,132,133],"Obstructive Sleep Apnea of Adult","Sleep Apnea","Sleep Disorder","Blood Pressure","Endothelial Dysfunction","Oxidative Stress","RECRUITING","2026-04-27",{"date":137,"type":42},"2026-05-01",{"date":139,"type":42},"2023-01-01",{"date":141,"type":21},"2027-12-30",{"name":143,"class":49},"University of Calgary",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100532064","stepcare-extended-follow-up-substudy-100532064","NCT06207942","Stepcare Extended Follow-up Substudy","Extended Follow-up Substudy of the Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation -STEPCARE Trial","All OHCA participants randomized in the STEPCARE trial at the extended follow-up participating sites, who survive and provide consent, with no further inclusion or exclusion criteria.\n\nThe inclusion and exclusion criteria for the STEPCARE trial are:\n\n* Inclusion criteria: out-of-hospital cardiac arrest of non-traumatic origin, minimum of 20 minutes without chest compressions (defined as stable return of spontaneous circulation. ROSC), unconsciousness (defined as not being able to obey verbal commands equal to a FOUR-score motor response of \\\u003C4, or being intubated and sedated because of agitation after sustained ROSC, eligible for intensive care without restrictions or limitation, inclusion within 4 hours (240 minutes) of ROSC (or 220 minutes of stable ROSC).\n* Exclusion criteria: on ECMO prior to randomization, pregnancy, suspected or confirmed intracranial hemorrhage, previously randomized in the STEPCARE trial.\n\nFor caregivers, the eligibility will be that they live with, or have weekly or more frequent contact (in person or over the telephone) with the post OHCA survivor. Only one nominated caregiver per post OHCA survivor will be able to be included in the study. This would typically be the caregiver that would identify as the primary caregiver of the post OHCA survivor if needed, but may also be another close family member.",{"count":152,"type":21},600,[24],"To provide detailed information on long-term outcomes in relation to potential neuroprotection and improvements in recovery for different targets of sedation, temperature, and pressure management in post out of hospital cardiac arrest survivors at 6 and 12 months. In addition, the impact of caring for a post OHCA survivor will be explored.",[156,68,157,158],"Cardiac Arrest With Successful Resuscitation","Cognitive Impairment","Caregiver Burden","2025-04-17",{"date":161,"type":42},"2025-04-23",{"date":163,"type":42},"2023-08-01",{"date":165,"type":21},"2027-07-31",{"name":167,"class":49},"Region Skane",34]